Castle Biosciences Q1 revenue falls to $83.7 million; 2026 revenue guidance raised
Castle Biosciences reported first-quarter 2026 revenue of $83.7 million, down from $88.0 million a year earlier, and raised its full-year 2026 revenue guidance to $345-355 million from $340-350 million. The net loss narrowed to $14.5 million from $25.8 million, but the prior-year period included a one-time $20.1 million amortization charge, and revenue declined year over year.
Key points
- Q1 2026 revenue was $83.7 million, compared with $88.0 million in Q1 2025.
- Net loss was $14.5 million, or $0.49 per share, versus a net loss of $25.8 million, or $0.90 per share, a year earlier.
- 2026 total revenue guidance was raised to $345-355 million from $340-350 million.
- Cash, cash equivalents and marketable investment securities totaled $261.7 million as of March 31, 2026; net cash used in operations was $22.1 million.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.